Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Debate Moves To Center Of Presidential Campaigns

Executive Summary

The outcome of House/Senate negotiations over drug re-importation and taxpayer funded research will be the most pressing pharmaceutical-related issues in Washington, D.C., as the Medicare drug benefit debate takes center stage in the Presidential campaign.

You may also be interested in...



Pharmacies Should Have Same Right To Import As Manufacturers - NCPA

Licensed pharmacists should have the same right to import and re-import prescription drugs as manufacturers, the National Community Pharmacists Association maintained in an Aug. 24 letter to the House and Senate conferees on the Agriculture Appropriations bill (HR 4461).

Gore Links Pharmaceutical Industry To GOP, Bush In Acceptance Speech

Vice President Al Gore highlighted his willingness to fight pharmaceutical industry pressure as a point of difference between himself and Texas Gov. George W. Bush during his acceptance speech at the Democratic national convention Aug. 17 in Los Angeles.

PBMs Would Compete For Medicare Enrollees Under Sen. Roth's Rx Drug Plan

Medicare would contract with multiple pharmaceutical benefit managers in each service area under Sen. Roth's (R-Del.) Medicare reform plan.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel